About
Evogene is a computational biology company focused on revolutionizing product discovery and development in multiple life sciences-based industries, including human health and agriculture, through the use of its broadly applicable computational predictive biology (CPB) platform.
The CPB platform, incorporating a deep understanding of biology leveraged through the power of big data and artificial intelligence, has been designed to computationally discover and guide the development of life sciences products based on microbes, small molecules, and genetic elements.
Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd, medical cannabis through Canonic Ltd, agricultural biologicals through Lavie Bio Ltd, agriculture chemicals through AgPlenus Ltd, and agriculture solutions for castor oil production through Castera Ltd.
Funding history · 6 rounds · $135.7M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Evogene become a publicly traded company on NASDAQ?
- Evogene became public on NASDAQ in November 2013.
- What was the amount of the PIPE funding round Evogene received in August 2008, and who were the lead investors?
- In August 2008, Evogene received $18,000,000 in a PIPE funding round, with Monsanto as a lead investor.
- Which company acquired the activity of Evogene's subsidiary, Lavie Bio, in April 2025?
- In April 2025, ICL acquired the activity of Evogene's subsidiary, Lavie Bio.
- What was the focus of the collaboration announced in February 2026 between Evogene and Queensland University of Technology (QUT)?
- In February 2026, Evogene and Queensland University of Technology (QUT) announced a collaboration to advance AI-driven cancer therapeutics.
- What was the purpose of the expanded collaboration between Evogene and Google Cloud announced in February 2026?
- In February 2026, Evogene announced an expanded collaboration with Google Cloud to integrate AI agents into ChemPass AI™.
- What was the outcome of the collaboration between Evogene and Shanghai Lishan Biopharmaceuticals Co. announced in February 2026?
- In February 2026, Evogene and Shanghai Lishan Biopharmaceuticals Co. announced an exclusive licensing agreement for BMC128, a microbiome-based therapeutic for renal and lung cancer.
- What was the focus of the collaboration between Evogene and Unravel Biosciences announced in January 2026?
- In January 2026, Evogene and Unravel Biosciences announced a collaboration to develop a first-in-class therapy to reverse neurological damage in demyelinating disorders.
- What was the key milestone achieved by Evogene in collaboration with Google Cloud in June 2025?
- In June 2025, Evogene announced the completion of a first-in-class foundation model for generative molecule design, developed in collaboration with Google Cloud.
- What was the purpose of the collaboration announced in October 2024 between Evogene and Google Cloud?
- In October 2024, Evogene announced a collaboration with Google Cloud to pioneer a generative AI foundation model for novel small molecule design.
- What was the outcome of the collaboration between Evogene's subsidiary Lavie Bio and Corteva Agriscience announced in July 2023?
- In July 2023, Lavie Bio announced a licensing agreement for bio-fungicides with Corteva Agriscience.